TxCell and Ferring collaborate with Trizell on lead product Ovasave
French biotech firm TxCell (FR: TXCL) on Friday announced a further enhancement to the development of its lead product Ovasave, an antigen-specific Treg cell-based immunotherapy for the treatment of inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis. TxCell’s shares rose 9.65% to 6.25 euros on the news.
The collaboration, option, development and license agreement between TxCell and privately-held Switzerland-headquartered Ferring International has been assigned to Trizell Holding, an affiliate member of the Dr Frederik Paulsen Foundation.
Trizell was established by the Dr Frederik Paulsen Foundation to provide specialist management and scientific and development expertise that is dedicated to advanced therapies, ie, cellular and gene therapies. This new class of highly promising biological therapies includes TxCell’s Ovasave.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze